Prematta et al Gadek JE, Hosea SW, Gelfand JA, et al. 1980. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly puriﬁed C1 inhibitor. New Engl J Med, 302:542–6. Gompels MM, Lock RJ, Abinum M, et al. C1 inhibitor deﬁciency: consensus document. Clin Exp Immunol, 139:379–94. Hosea SW, Santaella ML, Brown EJ, et al. 1980. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med, 93:809–12. Juers M, Groner A. Virus safety of current plasma derived C1-INH: The Aventis Behring experience. J Allergy Clin Immunol, 114:S96–S8. Kunschak M, Engl W, Maritsch F, et al. 1998. A randomized, controlled trial to study the efﬁcacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion, 38:540–9. Levi M, Choi G, Picavet C, et al. 2006. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deﬁciency. J Allergy Clin Immunol, 117:904–8. Longhurst HJ, Carr S, Khair K. 2007. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol, 147:11–7. Ohela K, Rasanen JA, Wagner O. 1973. Hereditary angio-neurotic oedema – genealogical and immunological studies. Ann Clin Res, 5:174–80. Pickering RJ, Kelly JR, Good RA, et al. 1969. Replacement therapy in hereditary angioedema - successful treatment of two patients with fresh frozen plasma. Lancet, 1:326–30. Prematta M, Gibbs JG, Pratt EL, et al. 2007. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immuol, 98:383–8. Rais M, Unzeitig J, Grant JA. 1999. Refractory exacerbations of hereditary angioedema with associated Helicobacter pylori infection. J Allergy Clin Immunol, 103:713–4. Rosen FS, Austen KF. 1969. The neurotic edema. N Engl J Med, 280:1356–7. Schneider L, Lumry W, Vegh A, et al. 2007. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol, 120:416–22. Terpstra FG, Kleijn M, Koenderman AH, et al. 2007. Viral safety of C1-inhibitor NF. Biologicals, 35:173–81. van Doorn MB, Burggraaf J, van Dam T, et al. 2005. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immuol, 116:876–83. Visy B, Fust G, Bygum A, et al. 2007. Helicobacter pylori infection as a trigger factor of attacks in patients with hereditary angioedema. Helicobacter, 12:251–7. Waytes AT, Rosen FS, Frank MM. 1996. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med, 334:1630–4. Zuraw B, Busse P, White M, et al. 2008. Efﬁcacy and safety of long-term prophylaxis with C1-Inhibitor (C1INH) concentrate in patients with hereditary angioedema (HAE). AAAAI Poster Presentation. March 2008. Philadelphia, PA. Zuraw BL, Schaefer O, Grant JA, et al. 2007. Results of a randomized double-blind controlled study of nanoﬁltered C1-inhibitor for the treatment of HAE attacks. ACAAI Poster Presentation, 9 Nov 2007. Dallas, TX. 982 Therapeutics and Clinical Risk Management 2008:4(5)